tiprankstipranks
Trending News
More News >
AlphaTON Capital (ATON)
NASDAQ:ATON
US Market

AlphaTON Capital (ATON) AI Stock Analysis

Compare
209 Followers

Top Page

ATON

AlphaTON Capital

(NASDAQ:ATON)

Select Model
Select Model
Select Model
Neutral 42 (OpenAI - 5.2)
Rating:42Neutral
Price Target:
$0.40
▼(-34.75% Downside)
Action:ReiteratedDate:02/05/26
The score is driven primarily by weak financial performance (no revenue, persistent losses, and ongoing cash burn with signs of equity erosion). Technicals reinforce the risk with bearish trend signals (price below key moving averages and negative MACD), while valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Recurring AI compute revenue
AlphaTON has begun generating recurring, hourly-rental revenue from deployed high-end GPUs tied to Telegram’s Cocoon AI. That creates a durable revenue stream and a clearer go-to-market (inference rental) model that can scale with additional GPU deployments and enterprise demand.
Low financial leverage
Minimal reported debt reduces near-term solvency risk and preserves flexibility to raise capital or deploy assets. For a cash-burning growth pivot, low leverage is a structural strength that lowers bankruptcy risk and leaves room for external financing without high fixed obligations.
Monetizing non-core biotech while retaining upside
The option-based sale of iOx transfers execution risk while preserving upside via equity, milestones and royalties. This materially reduces near-term R&D cash needs and refocuses capital allocation toward the AI infrastructure strategy, improving strategic clarity and cash conservation.
Negative Factors
No historical revenue base
The company historically lacks an established revenue base, meaning product-market fit and scalable demand remain unproven. Absent sustained revenue, margin sustainability and long-term profitability depend on successful execution of recent deployments and new monetization, not yet demonstrated.
Persistent cash burn
Negative operating and free cash flow across periods indicates ongoing cash burn that erodes equity and requires continual financing. This structurally constrains reinvestment, increases execution risk for scaling GPU fleets, and makes the company vulnerable if capital markets tighten.
Dependence on equity financings
The firm’s strategic plan relies heavily on raising equity (ATMs, registered offerings) to fund capex and expansion. Continued access to public markets is uncertain and makes the business model dependent on external capital rather than internal cash generation, which is a structural funding vulnerability.

AlphaTON Capital (ATON) vs. SPDR S&P 500 ETF (SPY)

AlphaTON Capital Business Overview & Revenue Model

Company DescriptionAlphaTON Capital Corp. is the rebranded entity formerly known as Portage Biotech Inc., a clinical-stage immuno-oncology company transitioning into a digital asset treasury model focused on accumulating and staking Toncoin (TON). AlphaTON intends to invest significantly in TON tokens, targeting a Long-Term TON treasury of approximately US $100 million.
How the Company Makes MoneyPortage Biotech Inc. generates revenue primarily through the development and commercialization of its proprietary cancer immunotherapy products. The company's revenue streams include licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies. These partnerships often involve milestone payments, royalties on sales, and joint development efforts that leverage Portage's innovative technologies. Additionally, the company may receive funding from grants and research collaborations that support the advancement of its therapeutic pipeline. Portage's focus on cutting-edge oncology solutions positions it to capitalize on the growing demand for effective cancer treatments, contributing to its financial performance.

AlphaTON Capital Financial Statement Overview

Summary
Overall financial quality is weak: the company reports no revenue across periods, persistent operating and net losses (including a very large FY2024 loss), and consistently negative operating/free cash flow indicating ongoing cash burn. Low reported debt helps reduce leverage risk, but equity erosion and a smaller asset base increase sustainability and funding risk.
Income Statement
12
Very Negative
Profitability is weak across the dataset: revenue is reported as 0 in all periods, while operating losses are persistent (EBIT is negative in every year and in TTM (Trailing-Twelve-Months)). Net losses are also significant, including a very large loss in FY2024 and continued losses in TTM. With no revenue base and consistently negative earnings, the income statement profile reflects an unproven/unstable operating model despite some improvement from the FY2024 trough.
Balance Sheet
38
Negative
Leverage appears low with total debt near zero in most periods, which reduces financial risk. However, equity has been volatile—dropping from very high levels historically to a modest level in TTM and even turning slightly negative in FY2025—suggesting meaningful capital erosion from ongoing losses. Total assets also declined sharply versus earlier years, indicating a smaller balance sheet and reduced financial cushion despite limited debt.
Cash Flow
22
Negative
Cash generation is a key concern: operating cash flow and free cash flow are negative in every period shown, including TTM (Trailing-Twelve-Months), implying ongoing cash burn. While the TTM cash burn is smaller than some prior annual periods, free cash flow growth has been volatile and recently negative in TTM. Overall, the company appears dependent on external funding or balance-sheet drawdowns to sustain operations.
BreakdownTTMMar 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit0.00-35.00K-54.00K-1.00K0.000.00
EBITDA-16.37M-6.74M-18.20M-122.25M-14.77M-14.71M
Net Income-19.69M-6.77M-75.34M-104.61M-16.87M-15.83M
Balance Sheet
Total Assets30.59M2.23M7.78M99.13M194.66M174.86M
Cash, Cash Equivalents and Short-Term Investments183.00K1.67M5.03M10.54M23.35M2.77M
Total Debt0.000.0047.00K0.000.00150.00K
Total Liabilities21.70M3.05M4.45M23.73M29.23M27.26M
Stockholders Equity9.59M-123.00K4.02M76.05M121.20M101.45M
Cash Flow
Free Cash Flow-3.65M-5.46M-14.30M-12.08M-6.76M-3.28M
Operating Cash Flow-3.65M-5.46M-14.30M-12.07M-6.76M-4.28M
Investing Cash Flow-50.00K0.002.81M-617.00K0.00-860.00K
Financing Cash Flow2.12M2.10M5.97M-117.00K27.35M4.76M

AlphaTON Capital Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.61
Price Trends
50DMA
0.77
Negative
100DMA
2.63
Negative
200DMA
4.78
Negative
Market Momentum
MACD
-0.13
Negative
RSI
34.08
Neutral
STOCH
36.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATON, the sentiment is Negative. The current price of 0.61 is above the 20-day moving average (MA) of 0.56, below the 50-day MA of 0.77, and below the 200-day MA of 4.78, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 34.08 is Neutral, neither overbought nor oversold. The STOCH value of 36.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATON.

AlphaTON Capital Risk Analysis

AlphaTON Capital disclosed 28 risk factors in its most recent earnings report. AlphaTON Capital reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
We rely on information technology and security systems and any damage, interruption or compromise of our information technology and security systems or data could disrupt and harm our business. Q1, 2023
2.
Any actual or perceived failure by us to comply with government or other obligations related to privacy or data protection could adversely affect our business. Q1, 2023

AlphaTON Capital Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
53
Neutral
$13.31M-0.32-145.42%79.31%
48
Neutral
$8.96M-0.23-81.97%-46.88%34.83%
46
Neutral
$12.49M-0.51-107.58%83.95%
46
Neutral
$5.11M-0.10-168.18%71.57%
42
Neutral
$5.99M>-0.01
41
Neutral
$5.84M
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ATON
AlphaTON Capital
0.42
-4.18
-90.97%
CANF
Can-Fite BioPharma
4.65
-30.55
-86.79%
PHIO
Phio Pharmaceuticals
1.03
-0.54
-34.39%
CLRB
Cellectar Biosciences
3.38
-5.41
-61.55%
MTVA
MetaVia
1.55
-15.61
-90.97%
BOLT
Bolt Biotherapeutics
5.05
-4.68
-48.10%

AlphaTON Capital Corporate Events

AlphaTON Capital Leases 504 Nvidia B200 GPUs to Scale Confidential AI Infrastructure in Canada
Feb 18, 2026

On February 17, 2026, AlphaTON Capital announced it had signed and closed a $30 million AI compute infrastructure lease, adding 504 Nvidia Blackwell B200 GPUs to its Canadian deployment in a move that management says should deliver an estimated minimum $1.2 million in monthly revenue from March 2026 via hourly rentals to AI developers, enterprises and users in the Telegram ecosystem. The deployment, which follows a November 2025 pilot B200 fleet for Telegram’s Cocoon AI network and a January 2026 agreement to acquire 576 B300 GPUs for delivery in March, underscores the company’s ability to secure scarce high-end chips, pursue capital‑efficient growth through leasing and position Canada as a hub for privacy‑centric, confidential AI infrastructure amid surging global demand and tightening data‑sovereignty rules.

AlphaTON said the 504 B200 chips, hosted in an energy‑efficient Canadian data center, are expected to support a 1.7x return multiple and a 40% internal rate of return while helping scale its confidential compute capacity without overburdening the balance sheet. The company believes rapid expansion across its three recent GPU implementations, together with rising regulatory pressure for sovereign and privacy‑preserving AI outside Big Tech platforms, enhances its competitive position as a specialist AI infrastructure provider to the Telegram network and offers public investors leveraged exposure to the growth of confidential AI workloads.

The most recent analyst rating on (ATON) stock is a Hold with a $0.49 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Signs Option Deal to Sell iOx Therapeutics to Immunova While Retaining Biotech Upside
Feb 18, 2026

On February 17, 2026, AlphaTON Capital Corp. reported that it had executed a binding call option agreement granting Immunova, LLC, or an affiliate, the right to acquire iOx Therapeutics Limited, its wholly owned biotech subsidiary focused on liposomal iNKT agonists. Under the structure announced that day, AlphaTON would receive upfront cash at closing if the option is exercised, a 10% fully diluted equity stake in the acquiring entity, potential milestone payments that could exceed $100 million, and single‑digit royalties on future net sales, enabling the company to retain long-term economic exposure to iOx’s pipeline.

iOx’s lead asset, PORT-2 (IMM60), a liposomal iNKT cell agonist originating from the University of Oxford, has shown tolerability, biomarker-based immune activation, and early anti-tumor signals in Phase 1/2 IMP-MEL (IMPORT-201) studies in advanced melanoma and metastatic NSCLC, supported by a prior collaboration in which Merck supplied pembrolizumab. Management framed the transaction as a way to unlock value from a legacy biotech asset while handing development to Immunova’s specialized lipid-science platform, allowing AlphaTON to sharpen capital allocation toward its Telegram-centered technology strategy, including a mesothelioma program with TT-4 and an AI-driven rare-cancer initiative, though completion of the deal remains contingent on Immunova securing financing and other customary closing conditions.

The option-based divestiture underscores AlphaTON’s ongoing portfolio realignment as it balances its role as a Telegram ecosystem hyperscaler with the monetization of non-core biotech holdings. For shareholders, the deal structure is designed to preserve upside through equity, milestones, and royalties if iOx’s immune-oncology programs advance clinically, while limiting near-term development spend and execution risk on a specialized oncology platform now intended to be advanced under Immunova’s control.

The most recent analyst rating on (ATON) stock is a Hold with a $0.49 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Launches $400 Million ATM Share Offering to Fund Cocoon AI and Strategic Deals
Feb 17, 2026

On February 17, 2026, AlphaTON Capital Corp. entered into an at-the-market offering agreement with H.C. Wainwright & Co. that allows the company to sell up to $400 million of its ordinary shares from time to time on Nasdaq and other U.S. trading venues. The agreement, carried out under an effective F-3 shelf registration, gives AlphaTON and the sales agent flexibility to start, pause or terminate sales, with H.C. Wainwright earning up to a 3% commission on gross proceeds.

The move provides AlphaTON with a scalable equity financing channel as it ramps capital expenditures for Cocoon AI, including purchases of servers, GPUs and related infrastructure. Proceeds may also fund strategic transactions in complementary technologies and businesses as well as working capital and general corporate needs, signaling an effort to strengthen the company’s balance sheet and strategic optionality in the AI and technology markets.

The most recent analyst rating on (ATON) stock is a Hold with a $0.49 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Unwinds 2025 Share Exchange With Compedica
Feb 10, 2026

On February 6, 2026, AlphaTON Capital Corp entered into an agreement with Compedica Holdings Limited to terminate and rescind their June 5, 2025 Subscription Agreement, under which AlphaTON had issued 625,000 of its ordinary shares at $8.00 per share in exchange for 1,165,501 Compedica shares at $4.29 per share. The deal fully unwinds that prior share-for-share exchange by returning each party’s securities free of encumbrances, provides mutual releases and indemnification, and is intended to restore both companies to their pre-transaction positions without additional consideration, potentially simplifying AlphaTON’s capital structure and clarifying liabilities arising from the original arrangement.

The agreement, signed and closed on the same date, includes customary representations, warranties and termination provisions, while explicitly characterizing the rescission as a business decision rather than an admission of wrongdoing. By incorporating this action into existing registration statements, AlphaTON formally records the reversal of the strategic share swap, which may affect how investors assess its exposure to Compedica and its balance-sheet composition for the period following the 2025 transaction.

The most recent analyst rating on (ATON) stock is a Hold with a $0.49 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Announces Board Resignation and New Director Appointment
Feb 6, 2026

On February 5, 2026, director Steven Mintz informed AlphaTON Capital Corp of his decision to resign from the company’s board of directors, with the resignation becoming effective on February 6, 2026. On the same day, February 6, 2026, the board unanimously approved the appointment of F. Daniel Siciliano as a new member of the board, signaling a rapid transition designed to maintain continuity in the company’s governance structure and board oversight for shareholders and other stakeholders.

The most recent analyst rating on (ATON) stock is a Hold with a $0.49 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Raises $44 Million and Begins Generating AI Infrastructure Revenue for Telegram Cocoon AI
Jan 28, 2026

On January 28, 2026, AlphaTON Capital reported that it has raised a net $44 million in capital, deployed revenue-generating AI infrastructure for Telegram’s Cocoon AI network, and is broadening its role as a foundational provider of confidential, privacy-preserving AI compute tied to the Telegram ecosystem. Since late 2025 the company has executed a $15 million registered direct equity offering and committed $46 million to expand its GPU fleet with 576 NVIDIA B300 chips slated for delivery in March 2026, exited SEC “baby-shelf” limitations via a large shelf registration, launched multiple high-end GPU deployments that began generating Cocoon AI inference revenue in December, secured 2.2MW of renewable-powered data center capacity in Sweden, and signed strategic partnerships including a revenue-generating Midnight Foundation federated node agreement and the open-source AlphaTON Claude Connector integrating Anthropic’s AI with the TON blockchain on Telegram. Management framed these moves as completing the company’s pivot from a passive digital asset holder to an active, vertically integrated infrastructure operator within Telegram’s ecosystem, aiming to drive recurring revenues and strengthen its positioning at the intersection of AI, blockchain, and privacy-focused digital identity.

The most recent analyst rating on (ATON) stock is a Hold with a $0.57 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Raises $15 Million in Registered Direct Offering to Scale Cocoon AI
Jan 15, 2026

On January 13, 2026, AlphaTON Capital Corp entered into a securities purchase agreement for a registered direct offering of 15 million ordinary shares or pre-funded warrants at $1.00 per security, with closing completed on January 14, 2026, generating approximately $13.6 million in net proceeds after fees. The capital raise, arranged with H.C. Wainwright & Co. as exclusive placement agent and accompanied by placement agent warrants, is intended to fund the scaling of GPU deployments for AlphaTON’s Cocoon AI platform as well as working capital and general corporate purposes, while customary issuance restrictions and a one-year prohibition on variable rate financings underscore efforts to manage dilution and financing risk as the company deepens its position in the TON and Telegram-related technology ecosystem.

The most recent analyst rating on (ATON) stock is a Sell with a $0.86 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Files Q2 2025 Interim Results, Revealing Major Digital Asset-Driven Balance Sheet Expansion
Jan 13, 2026

On January 12, 2026, AlphaTON Capital Corp filed a Form 6-K for January 2026, furnishing unaudited condensed consolidated interim financial statements and management’s discussion and analysis for the three and six months ended September 30, 2025. The filing shows a substantial expansion of the balance sheet over the period, with total assets rising to $30.6 million from $2.2 million as of March 31, 2025, driven largely by the addition of stablecoins, TON and Bitcoin holdings, and digital asset receivables, while current liabilities increased to $21.5 million, primarily reflecting a sizable put right liability. Shareholders’ equity improved from a deficit of $0.8 million at March 31, 2025 to positive equity of $8.9 million at September 30, 2025, indicating a material strengthening of the company’s capital position even as accumulated deficits remain significant, a shift that could meaningfully affect its financial flexibility and risk profile for investors in the evolving digital-asset financing space.

The most recent analyst rating on (ATON) stock is a Sell with a $0.88 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Ends At-The-Market Share Offering Agreement With Chardan
Jan 9, 2026

On November 25, 2025, AlphaTON Capital Corp. filed a prospectus supplement with the U.S. Securities and Exchange Commission to offer and sell up to approximately $15.3 million of its ordinary shares under an at-the-market (ATM) offering agreement with Chardan Capital Markets LLC. However, that ATM Agreement, originally dated July 31, 2025, was subsequently terminated effective immediately on December 24, 2025, signaling a halt to this specific equity-raising program and potentially indicating a shift in AlphaTON Capital’s funding strategy or market approach going into 2026.

The most recent analyst rating on (ATON) stock is a Sell with a $0.58 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Partially Unwinds September 2025 Private Placement After Investor Exercises Put Option
Dec 31, 2025

On December 8, 2025, AlphaTON Capital Corp was required to honor a previously disclosed put option granted to certain investors in connection with its September 25, 2025 private placement financing. Under a side letter agreement, one investor exercised its right to have the company repurchase 658,644 ordinary shares at the original consideration value, compelling AlphaTON to transfer back 1,230,590.71 locked TON tokens and 187,515.21 liquid TON tokens with no adjustment for market value. The transaction effectively reverses part of the September financing and underscores the potential liquidity and balance-sheet impact of these contingent repurchase obligations on the company and its token-based capital structure.

The most recent analyst rating on (ATON) stock is a Sell with a $0.58 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Unwinds TON Treasury Deal With DWF in $15 Million Settlement
Dec 31, 2025

On December 30, 2025, AlphaTON Capital Corp entered into a Settlement Agreement and Release with DWF MaaS Limited to resolve disputes over rights and obligations arising from an August 25, 2025 Treasury Management Agreement under which DWF had been appointed to manage a portion of AlphaTON’s TON treasury strategy. The settlement follows DWF’s September 25, 2025 subscription for 105,000 ordinary shares and pre-funded warrants to purchase up to 2,513,240 additional shares for $15 million, as well as a separate issuance of 160,000 restricted shares that were to vest over three years. Under the terms of the Settlement Agreement, AlphaTON will repurchase the previously issued shares and pre-funded warrants from DWF for $15 million (or the remaining amount in the original funding wallet), remove vesting restrictions on the 160,000 restricted shares, pay DWF $35,000, and mutually release all claims, while terminating both the Treasury Management Agreement and the Restricted Share Agreement, effectively unwinding the earlier financing and management arrangements with DWF.

The most recent analyst rating on (ATON) stock is a Sell with a $0.58 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

AlphaTON Capital Discloses Immediate Resignation of Director Alexander Pickett
Dec 23, 2025

On December 19, 2025, AlphaTON Capital Corp announced that board member Alexander Pickett had resigned from the company’s board of directors, effective immediately, a governance change that may prompt adjustments to the board’s composition and committee assignments. The resignation was formally reported in a Form 6-K filed on December 23, 2025, which also confirms the company’s continued use of existing SEC registration statements, underscoring that this leadership change comes as AlphaTON maintains its established capital markets framework for investors.

AlphaTON Capital Initiates $15.3M ATM Offering
Nov 26, 2025

On November 25, 2025, AlphaTON Capital Corp announced the filing of a prospectus supplement with the SEC for the sale of up to $15,307,818 of its ordinary shares under an At-The-Market Offering Agreement with Chardan Capital Markets. This move is part of a strategic effort to raise capital through flexible market transactions, potentially impacting the company’s financial operations and market presence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 05, 2026